Genomic Study of Cutis Tricolor (Cutis Tricolor)
Primary Purpose
Pigmentary; Dermatosis
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Blood sample
Cutaneous biopsy
High troughput sequencing of human's exome
Sponsored by
About this trial
This is an interventional other trial for Pigmentary; Dermatosis
Eligibility Criteria
Inclusion Criteria: Patients with Cutis Tricolor in trio (an affected parent, an unaffected parent) or in duo (one of the two affected parents) Age : from 4 to 60 years Exclusion Criteria: Refusal to sign the informed consent Patient who doesn't have a social security scheme or beneficiary of such a scheme Pregnant or breastfeeding women Patient whith a legal protection measure (guardianship, curatorship) Patient under legal protection
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Cutis Tricolor patient included in trio or duo
Arm Description
Cutis Tricolor patient included in trio (one affected parent, one unaffected parent) or duo (one of the two affected parents)
Outcomes
Primary Outcome Measures
Number of patients in whom a pathogenic or probably pathogenic variant has been identified by exome sequencing
Secondary Outcome Measures
Number of patients in whom a pathogenic or probably pathogenic variant in the same gene as another patient in the series has been identified
Full Information
NCT ID
NCT06073171
First Posted
May 19, 2023
Last Updated
October 3, 2023
Sponsor
University Hospital, Montpellier
Collaborators
IntegraGen SA
1. Study Identification
Unique Protocol Identification Number
NCT06073171
Brief Title
Genomic Study of Cutis Tricolor
Acronym
Cutis Tricolor
Official Title
Genomic Study of Cutis Tricolor
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
March 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
Collaborators
IntegraGen SA
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
It's a study on Syndromic or Isolated Cutis Tricolor and had as main goal to identify the associated gene to the disease thanks to genetic analysis on minors patients and their parents reach by cutis Tricolor or not.
Detailed Description
Cutis Tricolor (CT) is a rare cutaneous anomaly defined by pigmentary disorders associating large hyper- and hypopigmented macules of immediate proximity, selectively affecting the trunk. CT can be isolated, sporadic or integrated as a complex syndromic form such as Ruggieri-Happle syndrome (RHS) or various forms of pigmentovascular phacomatosis. A recent analysis of one case of RHS followed by CHU of Montpellier by whole exome sequencing allows the identification of a frameshift pathogen variant (heterozygous state) of a candidate gene.
The main objective is to confirm the association of the candidate gene with syndromic CT (SCT, Ruggierri-Happle syndrome) and non syndromic CT, from a genetic molecular blood and biopsy analysis of patients reach by CT and their parents presenting the disease or not. Furthermore, other objectives are to identify others associated candidates genes and to know better cutaneous pigmentary troubles factors, neurologics and eye abnormalities by identifying the differents cellulars pathways particularly the inflammatory pathway in the pathology of SCT.
First of all, it will have a pre-inclusion visit where Dr WILLEMS. M (Clinical Genetic Department - CHU Montpellier, France) and Pr BESSIS. D (Dermatology Department - CHU Montpellier, France) will explain the study's progress. Then, during the inclusion visit, families will sign inform consent for inclusion in the study. The same day, datas will be collected on demographic, clinical datas, including (i) a description of cutaneous, morphologic and extra-cutaneous anomalies and (ii) a cutaneous biopsy and (iii) a blood test will be done.
The genetics exams results will be return to patients during an usual follow-up visit, 12 months after their inclusion in the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pigmentary; Dermatosis
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cutis Tricolor patient included in trio or duo
Arm Type
Other
Arm Description
Cutis Tricolor patient included in trio (one affected parent, one unaffected parent) or duo (one of the two affected parents)
Intervention Type
Biological
Intervention Name(s)
Blood sample
Intervention Description
7.5 mL will be sampled on EDTA tube for each patient
Intervention Type
Biological
Intervention Name(s)
Cutaneous biopsy
Intervention Description
4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients
Intervention Type
Genetic
Intervention Name(s)
High troughput sequencing of human's exome
Intervention Description
Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
Primary Outcome Measure Information:
Title
Number of patients in whom a pathogenic or probably pathogenic variant has been identified by exome sequencing
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Number of patients in whom a pathogenic or probably pathogenic variant in the same gene as another patient in the series has been identified
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with Cutis Tricolor in trio (an affected parent, an unaffected parent) or in duo (one of the two affected parents)
Age : from 4 to 60 years
Exclusion Criteria:
Refusal to sign the informed consent
Patient who doesn't have a social security scheme or beneficiary of such a scheme
Pregnant or breastfeeding women
Patient whith a legal protection measure (guardianship, curatorship)
Patient under legal protection
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Didier BESSIS, Prof.
Phone
04 67 33 69 06
Email
d-bessis@chu-montpellier.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Marjolaine WILLEMS, Dr
Phone
04 67 33 65 64
Email
m-willems@chu-montpellier.fr
12. IPD Sharing Statement
Learn more about this trial
Genomic Study of Cutis Tricolor
We'll reach out to this number within 24 hrs